Adherence to American Association for the Study of Liver Diseases (AASLD) Guidelines and Predictors of Readmission in Cirrhotic Patients: A Single Center Experience


Introduction: Liver cirrhosis (LC) is a major cause of mortality and morbidity in the United States. American Association for the Study of Liver Disease (AASLD) has developed guidelines for the management of patients with LC. Methods: We conducted a one-year retrospective chart review study of patients admitted with LC related complication. Our primary outcome was adherence to AASLD guidelines for the management of variceal bleeding (VB), fluid overload and hepatocellular carcinoma (HCC) screening, and secondary outcome was re-admission rate within 30 days of discharge. Results: A total of 139 patients were reviewed. Majority were males (65%) and Caucasians (65%). The admission indication was mainly for fluid overload (39%), hepatic encephalopathy (36%) and VB (27%). The one-month readmission rate was 31%, of those 47% and 37% were admitted for hepatic encephalopathy and fluid overload respectively. Periodic screening for HCC was done in only 40% of patients. Ninety-five percent of patients admitted with VB received PPI, octreotride and antibiotics. Diet education was only documented in 9% of patients on discharge. Significant predictors for 30-day readmission included high MELD score, elevated creatinine, and taking diuretics/lactulose before hospitalization in addition to shorter length of stay. Conclusion: Compliance with AASLD guidelines was optimal for patients with VB. Further optimization is required for HCC screening and patient education. Multiple factors play a role in readmissions for patients with cirrhosis; this model helps to identify patients at risk for readmission and opens an area for quality improvement measures to avoid unnecessary hospitalizations.

Share and Cite:

Masadeh, M. , Zaied, A. , Hussain, F. , Spratt, H. and Soloway, R. (2015) Adherence to American Association for the Study of Liver Diseases (AASLD) Guidelines and Predictors of Readmission in Cirrhotic Patients: A Single Center Experience. Open Access Library Journal, 2, 1-8. doi: 10.4236/oalib.1101593.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] CDC/NCHS. National Hospital Discharge Survey (2010) Detailed Diagnosis and Procedure Tables; Number of First-Listed Diagnoses for Discharges from Short-Stay Hospitals, by ICD-9-CM Code, Sex, Age, and Geographic Region.
[2] Murphy, S., Xu, J. and Kochanek, K. (2013) Deaths: Final Data for 2010. National Vital Statistics Reports, 61, 1-118.
[3] Schuppan, D. and Afdhal, N.H. (2008) Liver Cirrhosis. The Lancet, 371, 838-851.
[4] Martínez-Noguera, A., Montserrat, E., Torrubia, S. and Villalba, J. (2002) Doppler in Hepatic Cirrhosis and Chronic Hepatitis. Seminars in Ultrasound, CT and MRI, 23, 19-36.
[5] Gines, P., Quintero, E., Arroyo, V., et al. (1987) Compensated Cirrhosis: Natural History and Prognostic Factors. Hepatology (Baltimore, Md), 7, 122-128.
[6] Runyon, B.A. (1994) Care of Patients with Ascites. The New England Journal of Medicine, 330, 337-342.
[7] Runyon, B.A. (2015) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th Edition, Saunders, Philadelphia, PA, Chapter 93, 1553.e5-1576.e5.
[8] Johnson, E.A., Spier, B.J., Leff, J.A., Lucey, M.R. and Said, A. (2011) Optimising the Care of Patients with Cirrhosis and Gastrointestinal Haemorrhage: A Quality Improvement Study. Alimentary Pharmacology & Therapeutics, 34, 76-82.
[9] Garcia-Tsao, G. and Bosch, J. (2010) Management of Varices and Variceal Hemorrhage in Cirrhosis. The New England Journal of Medicine, 362, 823-832.
[10] El-Serag, H.B. and Mason, A.C. (1999) Rising Incidence of Hepatocellular Carcinoma in the United States. The New England Journal of Medicine, 340, 745-750.
[11] Zhang, B.H., Yang, B.H. and Tang, Z.Y. (2004) Randomized Controlled Trial of Screening for Hepatocellular Carcinoma. Journal of Cancer Research and Clinical Oncology, 130, 417-422.
[12] Volk, M.L., Tocco, R.S., Bazick, J., Rakoski, M.O. and Lok, A.S. (2012) Hospital Readmissions among Patients with Decompensated Cirrhosis. The American Journal of Gastroenterology, 107, 247-252.
[13] Garcia-Tsao, G., Sanyal, A.J., Grace, N.D. and Carey, W. (2007) Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Hepatology (Baltimore, Md), 46, 922-938.
[14] Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N. and Conde, J.G. (2009) Research Electronic Data Capture (REDCap)—A Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support. Journal of Biomedical Informatics, 42, 377-381.
[15] Runyon, B.A. (2009) Management of Adult Patients with Ascites Due to Cirrhosis: An Update. Hepatology (Baltimore, Md), 49, 2087-2107.
[16] Bruix, J. and Sherman, M., American Association for the Study of Liver D (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology (Baltimore, Md), 53, 1020-1022.
[17] Berman, K., Tandra, S., Forssell, K., et al. (2011) Incidence and Predictors of 30-Day Readmission among Patients Hospitalized for Advanced Liver Disease. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 9, 254-259.
[18] Shu, C.C., Lin, Y.F., Hsu, N.C. and Ko, W.J. (2012) Risk Factors for 30-Day Readmission in General Medical Patients Admitted from the Emergency Department: A Single Centre Study. Internal Medicine Journal, 42, 677-682.
[19] Volk, M.L., Piette, J.D., Singal, A.S. and Lok, A.S. (2010) Chronic Disease Management for Patients with Cirrhosis. Gastroenterology, 139, 14e1-16e1.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.